Marine algal polysaccharides as future potential constituents against non-alcoholic steatohepatitis

被引:9
|
作者
Lu, Si-Yuan [1 ,3 ]
Tan, Karsoon [2 ]
Zhong, Saiyi [1 ]
Cheong, Kit -Leong [1 ,3 ]
机构
[1] Guangdong Ocean Univ, Coll Food Sci & Technol, Guangdong Prov Key Lab Aquat Prod Proc & Safety, Zhanjiang, Peoples R China
[2] Beibu Gulf Univ, Guangxi Key Lab Beibu Gulf Biodivers Conservat, Qinzhou, Guangxi, Peoples R China
[3] Shantou Univ, Coll Sci, Dept Biol, Guangdong Prov Key Lab Marine Biotechnol, Shantou, Guangdong, Peoples R China
关键词
NASH; Functional food; Seaweeds; LIVER-KIDNEY FUNCTIONS; AROMATIC-AMINO-ACIDS; SULFATED POLYSACCHARIDES; GUT MICROBIOTA; HEPATOCELLULAR-CARCINOMA; PHYSICOCHEMICAL PROPERTIES; UNDARIA-PINNATIFIDA; INSULIN-RESISTANCE; OXIDATIVE STRESS; FUCOIDAN;
D O I
10.1016/j.ijbiomac.2023.126247
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic steatohepatitis (NASH) is one of the most chronic and incurable liver diseases triggered mainly by an inappropriate diet and hereditary factors which burden liver metabolic stress, and may result in liver fibrosis or even cancer. While the available drugs show adverse side effects. The non-toxic bioactive molecules derived from natural resources, particularly marine algal polysaccharides (MAPs), present significant potential for treating NASH. In this review, we summarized the protective effects of MAPs on NASH from multiple perspectives, including reducing oxidative stress, regulating lipid metabolism, enhancing immune function, preventing fibrosis, and providing cell protection. Furthermore, the mechanisms of MAPs in treating NASH were comprehensively described. Additionally, we highlight the influences of the special structures of MAPs on their bioactive differences. Through this comprehensive review, we aim to further elucidate the molecular mechanisms of MAPs in NASH and inspire insights for deeper research on the functional food and clinical applications of MAPs.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810
  • [32] Fructose and Non-Alcoholic Steatohepatitis
    Roeb, Elke
    Weiskirchen, Ralf
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [33] Hepatocytic ballooning in non-alcoholic steatohepatitis: Dilemmas and future directions
    Li, Yang-Yang
    Zheng, Tian-Lei
    Xiao, Shu-Yuan
    Wang, Peng
    Yang, Wen-Jun
    Jiang, Li-Lin
    Chen, Li-Li
    Sha, Jun-Cheng
    Jin, Yi
    Chen, Sui-Dan
    Byrne, Christopher D.
    Targher, Giovanni
    Li, Jian-Min
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2023, 43 (06) : 1170 - 1182
  • [34] Metformin in non-alcoholic steatohepatitis
    Urso, R
    Visco-Comandini, U
    LANCET, 2002, 359 (9303): : 355 - 356
  • [35] Diagnosis of non-alcoholic steatohepatitis
    James, OFW
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 34 - 39
  • [36] News on non-alcoholic steatohepatitis
    Roeb, E.
    Nitschmann, S.
    INTERNIST, 2022, 63 (02): : 238 - 242
  • [37] Non-alcoholic steatohepatitis (NASH)
    Michael F. Sorrell
    Sandeep Mukherjee
    Current Treatment Options in Gastroenterology, 1999, 2 (6) : 447 - 450
  • [38] Statins in Non-alcoholic Steatohepatitis
    Torres-Pena, Jose D.
    Martin-Piedra, Laura
    Fuentes-Jimenez, Francisco
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [39] Non-alcoholic Steatohepatitis: An Overview
    Shifflet, Allison
    Wu, George Y.
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (01) : 4 - 12
  • [40] Cannabis and non-alcoholic steatohepatitis
    Cohen, L. B.
    Neuman, M. G.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 51 - 51